Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

FDA Grants Accelerated Approval to Epcoritamab for Relapsed/Refractory Follicular Lymphoma

June 26th 2024

The FDA has granted accelerated approval to epcoritamab-bysp (Epkinly) for the treatment of adult patients with relapsed or refractory follicular lymphoma following 2 or more lines of systemic therapy.

Dr Erba on the Safety of Quizartinib By Treatment Phase and Age in FLT3-ITD–positive AML

June 25th 2024

Harry Erba, MD, PhD, discusses the safety profile of quizartinib according to treatment phase and age in newly diagnosed patients with FLT3-ITD–positive acute myeloid leukemia.

Dr Bansal on Outpatient Administration With Axi-Cel and Brexu-Cel in R/R NHL

June 25th 2024

Radhika Bansal, MBBS, discusses outpatient administration of axi-cel and brexu-cel in relapsed/refractory non-Hodgkin lymphoma.

Phase 3 Study Results of Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Versus VRd for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma (IMROZ)

June 25th 2024

IMROZ (NCT03319667) is the first global Phase 3 study of an anti-CD38 mAb in combination with VRd in patients with transplant-ineligible NDMM.

Dr Winter on Unmet Needs in Richter Transformation for Patients With CLL

June 24th 2024

Allison Winter, MD, discusses unmet needs for patients with Richter transformation from CLL.

Dr Ip on the Impact of BCMA Alternative Splicing in Lymphoma and Multiple Myeloma

June 24th 2024

Andrew Ip, MD, discusses alternative splicing of the TNFRSF17 gene, which encodes BCMA, in patients with lymphoma or multiple myeloma.

FDA Approves Crovalimab for Paroxysmal Nocturnal Hemoglobinuria

June 24th 2024

The FDA has approved crovalimab for patients 13 years of age and older with paroxysmal nocturnal hemoglobinuria and a body weight of at least 40 kg.

Dr Winer on the Rationale for the TakeAim Leukemia Trial in Mutated AML

June 21st 2024

Eric Winer, MD, discusses the rationale for the phase 1/2a TakeAim Leukemia trial of emavusertib in patients with R/R FLT3- and spliceosome-mutated AML.

Dr Al Malki on Outcomes With PTCy-Based GVHD Prophylaxis in Hematologic Malignancies

June 21st 2024

Monzr M. Al Malki, MD, discusses outcomes with mismatched unrelated donor transplantation using post-transplant cyclophosphamide–based GVHD prophylaxis.

Ongoing Research Efforts and More in Ph+ Acute Lymphoblastic Leukemia

June 21st 2024

Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss ongoing research efforts in the treatment paradigm of Philadelphia chromosome–positive acute lymphoblastic leukemia.

Dr Jimenez Jimenez on PBSC from HLA-Mismatched Donors in Hematological Malignancies

June 21st 2024

Antonio Martin Jimenez Jimenez, MD, discusses conditioning therapy, PBSC from HLA-MMUD, and PTCy for GVHD prophylaxis in hematological malignancies.

Safety Data With Ponatinib in PHALLCON for Ph+ Acute Lymphoblastic Leukemia

June 21st 2024

Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss safety findings from the PHALLCON trial of ponatinib in Philadelphia chromosome–positive acute lymphoblastic leukemia.

Clinical Efficacy With Ponatinib in the PHALLCON Trial for Ph+ ALL

June 21st 2024

Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss the efficacy with ponatinib observed in the PHALLCON trial of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.

The Impact of the Ponatinib FDA Approval in Newly Diagnosed Ph+ ALL

June 21st 2024

Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss the impact of the FDA approval of ponatinib for the treatment of newly diagnosed patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.

Current Standards of Care for Ph+ Acute Lymphoblastic Leukemia

June 21st 2024

Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss current standards of care for the treatment of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.

Prevalence and Prognosis of Ph+ Acute Lymphoblastic Leukemia

June 21st 2024

Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss the prevalence and prognostic outcomes of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.

MB-106 Shows Early Promise in BTKi-Refractory Waldenström Macroglobulinemia/LPL

June 21st 2024

MB-106 showcased a favorable safety profile and elicited responses in heavily pretreated patients with refractory Waldenström macroglobulinemia.

Dr Deininger on Long-Term Outcomes With Ponatinib in T315I-Mutant CP-CML

June 20th 2024

Michael Deininger, MD, PhD, discusses 4-year outcomes with ponatinib in patients with chronic myeloid leukemia harboring a T315I mutation.

Dr Winter on Real-World Outcomes With Liso-Cel in Richter Transformation

June 20th 2024

Allison Winter, MD, discusses data from a retrospective analysis evaluating real-world outcomes with liso-cel in patients with Richter transformation.

Dr Hantel on Socioeconomic Influences on First-Line Treatment in AML

June 18th 2024

Andrew Hantel, MD, discusses the influence of race/ethnicity and socioeconomic status on the timeliness of first-line treatment in acute myeloid leukemia.